Category: In the News

WASHINGTON, June 4, 2025 /PRNewswire/ — A collection of public and private sector health leaders today announced a new collaboration to help ensure current health screening measures remain aligned with the rapid advancements in FDA-approved screening technologies and clinical guidelines. The Alliance for Screening Measurement Modernization (ASMM) brings together organizations from across the healthcare sector to…

Consistent, accurate diagnoses are the bedrock of precision oncology. The nonprofit Friends of Cancer Research (Friends) held a meeting in Washington, DC, as part of its ongoing work to understand diagnostic test variability in support of improving precision medicine. Invited speakers and panelists probed opportunities and challenges in the use of artificial intelligence (AI), alignment…

In a groundbreaking advancement for clinical trial methodology, the SWOG S2302 Pragmatica-Lung trial has demonstrated an innovative approach to cancer research, challenging traditional norms with its pragmatic design and broad eligibility criteria. Launched to assess whether a combination of ramucirumab (Cyramza) and pembrolizumab (Keytruda) could improve overall survival in patients with stage IV or recurrent…

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments. Importantly, the phase 3 trial’s rapid development and implementation,…

A clinical research initiative has demonstrated that artificial intelligence could significantly enhance the identification of patients eligible for targeted breast cancer therapies, according to preliminary findings presented by Friends of Cancer Research. The Digital PATH Project, involving 31 contributing partners including pharmaceutical companies, academic centers, and government agencies, represents one of the most comprehensive evaluations…

In a research project comparing the performance of 10 digital pathology tools capable of evaluating HER2 status from a common set of about 1,100 breast cancer samples, a key finding was the high level of agreement between their results and those of expert human pathologists—at least when the tumor marker was highly expressed. The greatest…

On May 9, the Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy hosted a public meeting focused on regulatory and manufacturing approaches to increase access to cell therapy products for small patient populations. Here, AgencyIQ provides a summary of the key points of discussion, including the FDA’s communication channels and postmarket surveillance.…

In a research project comparing the performance of 10 digital pathology tools capable of evaluating HER2 status from a common set of about 1,100 breast cancer samples, a key finding was the high level of agreement between their results and those of expert human pathologists—at least when the tumor marker was highly expressed. The greatest…

President Trump recently signed a wide-ranging executive order urging Congress to amend a crucial provision of a Biden-era law governing Medicare drug price negotiations, with the administration’s aim being to lower prices without kneecapping pharmaceutical industry investments in the research and development of innovative new drugs. The executive order marks this administration’s first health-policy intervention…

FDA Commissioner Marty Makary’s proposal to roll out a new drug approval pathway is heightening hope for the rare disease industry, but attorneys say implementation may face challenges for spurring rare drug development. Makary outlined on the Megyn Kelly Show in April a plan to approve drugs for rare conditions based on a “plausible mechanism,” allowing medicines…